NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.
Transfection Reagent for D-407 Cells (Retinal Pigment Epithelial Cells)
- Proprietary cationic lipids formulation
High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
Kit includes Transfection Enhancer reagent
Produces consistent results, lot-to-lot, plate-to-plate, and well-to-well
A proven reagent for establishing stable cell lines
Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
- Download PowerPoint presentation for D407 cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 70% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems D-407 Transfection Protocol: [PDF]
Download MSDS: [PDF]
D-407 Cell Line:
Despite recent breakthroughs in the treatment and prevention of eye diseases that lead to blindness, there are still many causes of visual impairment for which there is no treatment. Preclinical studies of the retinal pigment epithelium (RPE) can help to overcome obstacles in finding new treatments for age-related macular degeneration (AMD), the primary cause of blindness in the world. Retinal pigment epithelium (RPE) is a layer of cells in the eye that provides nourishment to retinal cells and performs a variety of functions related to the upkeep of normal vision. Over time the RPE degenerates and leads to a variety of vision disorders. The D-407 cell line was derived from human RPE cells and is a valuable research tool in the study of vision impairment. This cell line is useful in studies of human eye cells, further investigation of this cell line could produce potential medical treatments for the visually impaired. D-407 cells exhibit phagocytic activity and are used widely in molecular and cell biology research. Research carried out via transfection on the D-407 RPE cell line could lead to the development of treatments that could help restore vision in patients. Altogen Biosystems provides lipid-based transfection reagent kits for the D-407 retinal pigment epithelium cell line that has produced consistent results in the establishment of stable cell lines.
Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the D-407 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPDH mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated.
Figure 2. Protein expression of GAPDH in D-407 cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into D-407 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems provides preoptimized transfection products for life science research applications. Transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery to liver, pancreas, and kidney tissues), and broad range in vivo delivery reagents (PEG-Liposome, Nanoparticle-based, Lipid-based, and Polymer-based kits). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, RNA, and any other negatively charged molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #1743)
- 1.5 ml (Catalog #1744)
- 1.5 ml CRISPR (Catalog #2135)
- 8.0 ml (Catalog #7033)